1 Mid-Cap Stock to Research Further and 2 We Avoid
1 Cash-Producing Stock with Solid Fundamentals and 2 We Turn Down
The S&P 500 Index ($SPX ) (SPY ) on Friday closed down -0.05%, the Dow Jones Industrial Average ($DOWI ) (DIA ) closed down -0.09%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) closed down -1.09%. September...
The S&P 500 Index ($SPX ) (SPY ) today is down -0.07%, the Dow Jones Industrial Average ($DOWI ) (DIA ) is down -0.04%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is down -0.75%. September E-mini S&P futures...
If approved, Opzelura ® (ruxolitinib) cream will be the first steroid-free, topical JAK treatment option in the European Union (EU) for adults with moderate atopic dermatitis (AD)...
The S&P 500 Index ($SPX ) (SPY ) on Monday closed down -0.37%, the Dow Jones Industrial Average ($DOWI ) (DIA ) closed up +0.29%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) closed down -0.19%. September...
Incyte has rallied the healthcare sector over the past year, and analysts remain moderately optimistic about its prospects.
2 Growth Stocks to Add to Your Roster and 1 We Avoid
Incyte Biosciences Japan G.K. today announced that Japan’s Ministry of Health, Labour and Welfare (MHLW) has approved Minjuvi ® (tafasitamab) in combination with lenalidomide for the...
- Cohort 1 results presented at ENDO 2026 demonstrate meaningful reductions in total heterotopic ossification (HO) lesion volume, new HO lesions and flare activity in adolescents and adults with...